This report summarizes and reports next steps from an AVAC and FP2030 convened consultation with family planning (FP) and sexual and reproductive health (SRH) stakeholders. The aim of the consultation was to understand stakeholders’ unique perspectives on the Dual Prevention Pill (DPP), a daily oral pill that prevents HIV and pregnancy. The consultation helped to elevate questions and issues to consider as DPP introduction plans are refined and that can also inform the development and delivery of future multi-purpose prevention technologies (MPTs).
Consultation with FP/SRH Stakeholders on the Dual Prevention Pill
Multipurpose Prevention Technologies (MPTs): Technology Landscape and Potential for Low- and Middle-Income Countries
This landscape report provides an overview of the current novel technologies in development and assesses their relevance and potential in low- and middle-income countries. While the pipeline is rich, the report calls out the need to involve key populations early in the design, introduction and scale-up of new products and proactively address potential market barriers. These considerations, as well as plans for adoption, manufacturing capacity, a broad supply base and an effective introduction strategy are crucial to developing solutions that are accessible, affordable, and acceptable and truly respond to people’s needs.
HIV Prevention Research & Development Investments Report
The annual HIV Prevention Research and Development Investments Report reveals a growing mismatch between the current promise of HIV prevention R&D, and consistent declines in the funding available to both research new HIV prevention approaches and expand access to the prevention tools available today. The 2020 report, based on outreach to 215 funders of HIV prevention R&D in the public, philanthropic and commercial sectors, is the 16th annual report from the Resource Tracking for HIV Prevention Research & Development Working Group.
Read the report at hivresourcetracking.org.
AVAC’s Strategic Plan 2022-2026
AVAC’s strategic framework is grounded in a multi-layered approach that carefully considers all of the components needed to achieve the organization’s vision, capitalize on its key strengths, and ensure that AVAC is poised to make an impact on the issues it cares most about over the next five years, and beyond.
The vision describes the world we are striving for. The mission describes what AVAC does in service to achieving this vision. The strategic pillars outline the objectives and approaches that AVAC will take over the next five years to achieve its mission and vision. The strategic pillars are supported by AVAC’s core values—the principles by which we work—as well as a set of key enablers.
Advocate, Translate, Catalyze: For HIV prevention and health equity
In this document, we look at the actions we are taking and those that as a field we all need to take to transform prevention “options” developed through research into prevention “choices” for people that can save lives and help end epidemics. This work is critical, and it is shared – just as we developed our strategic plan and EDI statement in partnership with so many, so too will we move this work forward, together.
20 Essential Resources – Condoms & Family Planning
As recent-day family planning and reproductive health efforts place greater emphasis on innovation, it is important to remember the value of evidence-based family planning tools that have been effective for decades. Since the physical properties of condoms have not undergone substantial change, many people may forget the power of condoms as a family planning tool. This collection was created as a reminder to all of us that some methods continue to work even as innovations arise.
Global Investment in HIV Cure Research and Development in 2020
In 2014, the HIV Vaccines and Microbicides Resource Tracking Working Group and AVAC began a collaboration with the International AIDS Society’s (IAS) Towards an HIV Cure initiative. AVAC, Treatment Action Group (TAG) and the IAS brought together a group to review and allocate grants towards HIV cure research and analyze data on global funding. The working group released a report in July 2021, Global Investment in HIV Cure Research and Development in 2020.
A Situation Analysis Report on the Mobilization of Resources for Health Research & Development in Africa
This is a report commissioned by WACI Health in an effort to identify gaps, strengths and opportunities in health research funding. This aims at informing strategy and advocacy for all stakeholders committed to expanding the resources for health research and development (R&D) in Africa drawing from the experience and lessons from existing health R&D investments.
Where Is PEPFAR’s Strategy for Key Populations?
This document from Health GAP’s PEPFAR Watch is a community analysis of the success and challenges of PEPFAR’s Key Population program and recommendations for the next PEPFAR Ambassador.
BioPIC Adaptable Product Introduction Framework
This framework is intended to inform stakeholders involved in all stages of product introduction from clinical research to rollout in low- and middle-income countries (LMICs). While the framework focuses on activities to begin in parallel to phase III clinical trials, stakeholders in early product development phases may also want to understand what to expect in terms of downstream product introduction needs. Stakeholders involved in early product development may also consider leveraging some of the activities included to anticipate future needs.